CD38 and plasma cell myeloma: In a mouse xenograft model harboring NCI-H929 multiple myeloma cells, our BsAbs inhibited tumor growth more potently than the monospecific anti-CD47 ligand trap, anti-CD38 (isatuximab) or combination of isatuximab and an anti-CD47 ligand trap at the same molecular dose per body weight.